92.72 USD
-0.6 (-0.64%)
92.4801 USD
-0.24 (-0.26%)
Overall AZN gets a fundamental rating of 6 out of 10. We evaluated AZN against 192 industry peers in the Pharmaceuticals industry. While AZN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AZN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AZN was profitable.
In the past year AZN had a positive cash flow from operations.
AZN had positive earnings in each of the past 5 years.
In the past 5 years AZN always reported a positive cash flow from operatings.
1.2 Ratios
AZN has a better Return On Assets (8.21%) than 90.10% of its industry peers.
AZN's Return On Equity of 20.48% is amongst the best of the industry. AZN outperforms 91.15% of its industry peers.
AZN's Return On Invested Capital of 14.42% is amongst the best of the industry. AZN outperforms 93.23% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AZN is in line with the industry average of 12.71%.
The last Return On Invested Capital (14.42%) for AZN is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
AZN has a Profit Margin of 16.17%. This is amongst the best in the industry. AZN outperforms 89.06% of its industry peers.
AZN's Profit Margin has improved in the last couple of years.
AZN has a better Operating Margin (24.34%) than 90.63% of its industry peers.
In the last couple of years the Operating Margin of AZN has grown nicely.
AZN's Gross Margin of 81.90% is amongst the best of the industry. AZN outperforms 84.90% of its industry peers.
In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
AZN has about the same amout of shares outstanding than it did 1 year ago.
AZN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AZN is higher compared to a year ago.
2.2 Solvency
AZN has an Altman-Z score of 3.53. This indicates that AZN is financially healthy and has little risk of bankruptcy at the moment.
AZN has a better Altman-Z score (3.53) than 70.31% of its industry peers.
AZN has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as AZN would need 3.41 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.41, AZN belongs to the top of the industry, outperforming 86.98% of the companies in the same industry.
A Debt/Equity ratio of 0.61 indicates that AZN is somewhat dependend on debt financing.
AZN has a Debt to Equity ratio of 0.61. This is in the lower half of the industry: AZN underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.53 |
ROIC/WACC1.64
WACC8.81%
2.3 Liquidity
A Current Ratio of 0.88 indicates that AZN may have some problems paying its short term obligations.
AZN has a Current ratio of 0.88. This is amonst the worse of the industry: AZN underperforms 88.02% of its industry peers.
A Quick Ratio of 0.69 indicates that AZN may have some problems paying its short term obligations.
AZN has a worse Quick ratio (0.69) than 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
The Revenue has grown by 13.52% in the past year. This is quite good.
AZN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
The Earnings Per Share is expected to grow by 12.73% on average over the next years. This is quite good.
AZN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.18% yearly.
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.16, the valuation of AZN can be described as rather expensive.
Based on the Price/Earnings ratio, AZN is valued cheaper than 80.73% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.31. AZN is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 17.37, which indicates a rather expensive current valuation of AZN.
79.69% of the companies in the same industry are more expensive than AZN, based on the Price/Forward Earnings ratio.
AZN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.16 | ||
| Fwd PE | 17.37 |
4.2 Price Multiples
81.77% of the companies in the same industry are more expensive than AZN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AZN is valued cheaper than 80.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.05 | ||
| EV/EBITDA | 15.07 |
4.3 Compensation for Growth
AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of AZN may justify a higher PE ratio.
AZN's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.46
PEG (5Y)1.08
EPS Next 2Y13.64%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
AZN has a Yearly Dividend Yield of 1.79%. Purely for dividend investing, there may be better candidates out there.
AZN's Dividend Yield is rather good when compared to the industry average which is at 7.92. AZN pays more dividend than 92.19% of the companies in the same industry.
Compared to the average S&P500 Dividend Yield of 2.40, AZN is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.79% |
5.2 History
The dividend of AZN has a limited annual growth rate of 1.40%.
AZN has paid a dividend for at least 10 years, which is a reliable track record.
AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
52.89% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
AZN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
92.72
-0.6 (-0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner Change11.47%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap287.48B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target93.08 (0.39%)
Short Float %0.32%
Short Ratio1.89
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.79% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)2.95%
PT rev (3m)2.33%
EPS NQ rev (1m)-1.79%
EPS NQ rev (3m)-1.48%
EPS NY rev (1m)0.17%
EPS NY rev (3m)0.22%
Revenue NQ rev (1m)0.3%
Revenue NQ rev (3m)0.08%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.16 | ||
| Fwd PE | 17.37 | ||
| P/S | 4.95 | ||
| P/FCF | 30.05 | ||
| P/OCF | 18.99 | ||
| P/B | 6.26 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.07 |
EPS(TTM)4.6
EY4.96%
EPS(NY)5.34
Fwd EY5.76%
FCF(TTM)3.09
FCFY3.33%
OCF(TTM)4.88
OCFY5.27%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.46
PEG (5Y)1.08
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.53 |
F-Score7
WACC8.81%
ROIC/WACC1.64
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y13.09%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
What is the fundamental rating for AZN stock?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status of ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
Can you provide the profitability details for ASTRAZENECA PLC-SPONS ADR?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.16 and the Price/Book (PB) ratio is 6.26.
How financially healthy is ASTRAZENECA PLC-SPONS ADR?
The financial health rating of ASTRAZENECA PLC-SPONS ADR (AZN) is 4 / 10.